3HELIX

3Helix has developed a series of proprietary collagen hybridizing peptides that directly target the damaged collagen molecule. In addition to providing CHP as a research tool for laboratory use in academia and industry, 3Helix is advancing its compounds to enable new pathways to achieving diagnostic and therapeutic objectives. 3Helix is based in Salt Lake City, Utah. It was founded by Drs. Yang Li and Michael Yu based on the technology that they invented at the Johns Hopkins University.

Founded: 2016
Investment: $0.5M
Web-1: www.3helix.com